Can allogeneic hematopoietic cell transplant cure therapy-related acute leukemia?

Yazan F. Madanat, Aaron T. Gerds

Research output: Contribution to journalReview article

Abstract

Therapy-related myeloid neoplasms (t-MN) include both therapy-related myelodysplastic syndromes as well as therapy-related acute myeloid leukemia. These two entities were grouped together in the World Health Organization classification of AML due to having similarly poor outcomes and disease biology. Exposure to prior radiation therapy or chemotherapy for other malignant or benign conditions, namely autoimmune diseases or solid organ transplants, constitutes the principal risk factor to develop t-MN. Mechanisms for the development of t-MN include direct genotoxic damage from prior chemotherapy or radiation therapy exposure and the selection of pre-existing clones with malignant potential that are able to evolve with time and manifest as new cancers. Patients with t-MN are generally considered high-risk at the time of diagnosis and are commonly referred for consideration of an allogeneic hematopoietic cell transplantation, however, this patient population poses unique challenges, and little is known about the ideal sequence and timing of treatment. In this review, we summarize the data pertaining to transplant options, focusing on patient and disease characteristics in which transplantation may be most useful and populations where non-transplant options may also be considered.

Original languageEnglish (US)
Pages (from-to)104-113
Number of pages10
JournalBest Practice and Research: Clinical Haematology
Volume32
Issue number1
DOIs
StatePublished - Mar 2019
Externally publishedYes

Fingerprint

Transplants
Second Primary Neoplasms
Leukemia
Chemotherapy
Radiotherapy
Drug Therapy
Myelodysplastic Syndromes
Cell Transplantation
Therapeutics
Acute Myeloid Leukemia
Health
Population
Autoimmune Diseases
Clone Cells
Transplantation
Neoplasms

Keywords

  • Allogeneic
  • Leukemia
  • Myeloid
  • Therapy-related
  • Transplantation

ASJC Scopus subject areas

  • Oncology
  • Clinical Biochemistry

Cite this

Can allogeneic hematopoietic cell transplant cure therapy-related acute leukemia? / Madanat, Yazan F.; Gerds, Aaron T.

In: Best Practice and Research: Clinical Haematology, Vol. 32, No. 1, 03.2019, p. 104-113.

Research output: Contribution to journalReview article

@article{eac6132532c443af91babf19b7fdf9e4,
title = "Can allogeneic hematopoietic cell transplant cure therapy-related acute leukemia?",
abstract = "Therapy-related myeloid neoplasms (t-MN) include both therapy-related myelodysplastic syndromes as well as therapy-related acute myeloid leukemia. These two entities were grouped together in the World Health Organization classification of AML due to having similarly poor outcomes and disease biology. Exposure to prior radiation therapy or chemotherapy for other malignant or benign conditions, namely autoimmune diseases or solid organ transplants, constitutes the principal risk factor to develop t-MN. Mechanisms for the development of t-MN include direct genotoxic damage from prior chemotherapy or radiation therapy exposure and the selection of pre-existing clones with malignant potential that are able to evolve with time and manifest as new cancers. Patients with t-MN are generally considered high-risk at the time of diagnosis and are commonly referred for consideration of an allogeneic hematopoietic cell transplantation, however, this patient population poses unique challenges, and little is known about the ideal sequence and timing of treatment. In this review, we summarize the data pertaining to transplant options, focusing on patient and disease characteristics in which transplantation may be most useful and populations where non-transplant options may also be considered.",
keywords = "Allogeneic, Leukemia, Myeloid, Therapy-related, Transplantation",
author = "Madanat, {Yazan F.} and Gerds, {Aaron T.}",
year = "2019",
month = "3",
doi = "10.1016/j.beha.2019.02.011",
language = "English (US)",
volume = "32",
pages = "104--113",
journal = "Best Practice and Research in Clinical Haematology",
issn = "1521-6926",
publisher = "Bailliere Tindall Ltd",
number = "1",

}

TY - JOUR

T1 - Can allogeneic hematopoietic cell transplant cure therapy-related acute leukemia?

AU - Madanat, Yazan F.

AU - Gerds, Aaron T.

PY - 2019/3

Y1 - 2019/3

N2 - Therapy-related myeloid neoplasms (t-MN) include both therapy-related myelodysplastic syndromes as well as therapy-related acute myeloid leukemia. These two entities were grouped together in the World Health Organization classification of AML due to having similarly poor outcomes and disease biology. Exposure to prior radiation therapy or chemotherapy for other malignant or benign conditions, namely autoimmune diseases or solid organ transplants, constitutes the principal risk factor to develop t-MN. Mechanisms for the development of t-MN include direct genotoxic damage from prior chemotherapy or radiation therapy exposure and the selection of pre-existing clones with malignant potential that are able to evolve with time and manifest as new cancers. Patients with t-MN are generally considered high-risk at the time of diagnosis and are commonly referred for consideration of an allogeneic hematopoietic cell transplantation, however, this patient population poses unique challenges, and little is known about the ideal sequence and timing of treatment. In this review, we summarize the data pertaining to transplant options, focusing on patient and disease characteristics in which transplantation may be most useful and populations where non-transplant options may also be considered.

AB - Therapy-related myeloid neoplasms (t-MN) include both therapy-related myelodysplastic syndromes as well as therapy-related acute myeloid leukemia. These two entities were grouped together in the World Health Organization classification of AML due to having similarly poor outcomes and disease biology. Exposure to prior radiation therapy or chemotherapy for other malignant or benign conditions, namely autoimmune diseases or solid organ transplants, constitutes the principal risk factor to develop t-MN. Mechanisms for the development of t-MN include direct genotoxic damage from prior chemotherapy or radiation therapy exposure and the selection of pre-existing clones with malignant potential that are able to evolve with time and manifest as new cancers. Patients with t-MN are generally considered high-risk at the time of diagnosis and are commonly referred for consideration of an allogeneic hematopoietic cell transplantation, however, this patient population poses unique challenges, and little is known about the ideal sequence and timing of treatment. In this review, we summarize the data pertaining to transplant options, focusing on patient and disease characteristics in which transplantation may be most useful and populations where non-transplant options may also be considered.

KW - Allogeneic

KW - Leukemia

KW - Myeloid

KW - Therapy-related

KW - Transplantation

UR - http://www.scopus.com/inward/record.url?scp=85062207970&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062207970&partnerID=8YFLogxK

U2 - 10.1016/j.beha.2019.02.011

DO - 10.1016/j.beha.2019.02.011

M3 - Review article

C2 - 30927969

AN - SCOPUS:85062207970

VL - 32

SP - 104

EP - 113

JO - Best Practice and Research in Clinical Haematology

JF - Best Practice and Research in Clinical Haematology

SN - 1521-6926

IS - 1

ER -